A study of a GLP-1 medicine, liraglutide, in people with metabolic syndrome.
Recruiting now. Registry record last updated May 6, 2026.
- Who can join
- Adults 21 to 60, have metabolic syndrome, BMI 25+.
- What you take
- Liraglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The full study runs about 6 years.
- What you get
- Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
What this study is for
Primary condition: Metabolic Syndrome.
Full scientific study title: Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome.
Who can join
Adults 21 to 60, have metabolic syndrome, BMI 25+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Male or female ≥21 and ≤60 years old.
- Body mass index \>25 and ≤35 kg/m2 and is weight stable (\<5 kg weight change in the past 6 months). BMI is limited to ≤35 kg/m2 for easier vascular access and cardiac imaging.
- Meet 3 of 5 National Cholesterol Education Program Adult Treatment Panel III Metabolic Syndrome criteria:
- Increased waist circumference (≥102 cm in men; ≥88 cm in women)
- Elevated triglycerides (≥150 mg/dl)
Key exclusion criteria
- A diagnosis of any type of diabetes or history of diabetes medication use
- Recently active (\>20 min of moderate/high intensity exercise, 2 times/week)
- Subjects who are smokers or who have quit smoking \<5 years
- Subjects with hypertriglyceridemia (\>400 mg/dl) or hypercholesterolemia (\>260 mg/dl)
- Subjects with BP\>160/90
Where this trial is enrolling
This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.
Virginia1 site
- University of VirginiaCharlottesville, Virginia
Timeline
Started enrolling: November 1, 2020. Expected completion: April 30, 2027. Last updated on ClinicalTrials.gov: May 6, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
